IMVT Stock Analysis: Immunovant | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 6.864m USD | 12M Return: 40.4% | US45258J1025 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 39.2M
Qual. Beats: 1
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 7.4 years of data, until 10/2026
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.
Immunovant, Inc. is a clinical-stage immunology company developing targeted therapies for patients with autoimmune diseases. The company is headquartered in Durham, North Carolina, was founded in 2018, and trades on NASDAQ under the ticker IMVT within the Health Care sector (Biotechnology sub-industry).
Its lead candidate, IMVT-1402, is a human monoclonal antibody designed to inhibit the neonatal fragment crystallizable (FcRn) receptor, a mechanism being explored across multiple autoimmune indications including Graves disease, rheumatoid arthritis, Sjögrens disease, cutaneous lupus erythematosus, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. As a clinical-stage biopharmaceutical company, Immunovant is focused on advancing drug candidates through preclinical and clinical development rather than generating commercial product revenue, which is typical for firms at this stage of the biotech lifecycle.
Immunovant operates as a subsidiary of Roivant Sciences Ltd., reflecting the Roivant hub-and-spoke model in which a parent company establishes focused subsidiaries to develop individual therapeutic programs. With a mid-cap market capitalization, IMVT sits among the larger publicly traded clinical-stage immunology developers.
- IMVT-1402 Phase 3 trial readout in myasthenia gravis
- Competition intensifies from argenxs Vyvgart in FcRn market
- Cash burn widens as Roivant funds pipeline expansion
| Net Income: -509.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.52 > 0.02 and ΔFCF/TA 22.08 > 1.0 |
| NWC/Revenue: 9.25k% < 20% (prev 319k%; Δ -310k% < -1%) |
| CFO/TA -0.52 > 3% & CFO -395.0m > Net Income -509.0m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 7.31 > 1.5 & < 3 |
| Outstanding Shares: last quarter (206.7m) vs 12m ago 19.02% < -2% |
| Gross Margin: 94.24% > 18% (prev -144.4%; Δ 238.6% > 0.5%) |
| Asset Turnover: 1.06% > 50% (prev 0.03%; Δ 1.03% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.86 (Total Current Assets 760.0m - Total Current Liabilities 104.0m) / Total Assets 761.0m |
| B: -2.62 (Retained Earnings -2.00b / Total Assets 761.0m) |
| C: -0.76 (EBIT TTM -510.3m / Avg Total Assets 672.0m) |
| D: 6.32 (Book Value of Equity 656.9m / Total Liabilities 104.0m) |
| Altman-Z'' = -1.37 = CCC |
| DSRI: 0.10 (Receivables 138k/1.97m, Revenue 7.09m/160k) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 0.06 (AQ_t 0.00 / AQ_t-1 0.02) |
| SGI: 44.34 (Revenue 7.09m / 160k) |
| TATA: -0.15 (NI -509.0m - CFO -395.0m) / TA 761.0m) |
| Beneish M = 26.74 (Cap -4..+1) = D |
As of November 20, 2026, the stock is trading at USD 32.52 with a total of 731,036 shares traded. Over the past week, the price has changed by -7.22%, over one month by +17.74%, over three months by -27.67% and over the past year by +40.41%.
Current recommended Stop Loss: 28.60 (which is 12.1% or 2.5 ATR below the current price).
Immunovant has received a consensus analysts rating of 4.41. Therefore, it is recommended to buy IMVT.
- StrongBuy: 11
- Buy: 2
- Hold: 4
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 48.6 | 49.5% |
P/B = 10.468
Revenue TTM = 7.09m USD
EBIT TTM = -510.3m USD
EBITDA TTM = -509.9m USD
Long Term Debt = unknown (none)
Short Term Debt = 72.0k USD (from shortTermDebt, last fiscal year)
Debt = 72.0k USD (from shortLongTermDebtTotal, last fiscal year) (leases 72.0k already included)
Net Debt = -722.2m USD (calculated: Debt 72.0k - CCE 722.3m)
Enterprise Value = 6.14b USD (6.86b + Debt 72.0k - CCE 722.3m)
Interest Coverage Ratio = unknown (Ebit TTM -510.3m / Interest Expense TTM 0.0)
EV/FCF = -15.55x (Enterprise Value 6.14b / FCF TTM -395.0m)
FCF Yield = -6.43% (FCF TTM -395.0m / Enterprise Value 6.14b)
FCF Margin = -5.57k% (FCF TTM -395.0m / Revenue TTM 7.09m)
Net Margin = -7.17k% (Net Income TTM -509.0m / Revenue TTM 7.09m)
Gross Margin = 94.24% ((Revenue TTM 7.09m - Cost of Revenue TTM 409k) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 8.07 (Enterprise Value 6.14b / Total Assets 761.0m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 72.0k)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -403.1m (EBIT -510.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 7.31 (Total Current Assets 760.0m / Total Current Liabilities 104.0m)
Debt / Equity = 0.00 (Debt 72.0k / totalStockholderEquity, last quarter 656.9m)
Debt / EBITDA = 1.42 (negative EBITDA) (Net Debt -722.2m / EBITDA -509.9m)
Debt / FCF = 1.83 (negative FCF - burning cash) (Net Debt -722.2m / FCF TTM -395.0m)
Total Stockholder Equity = 807.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -75.74% (Net Income -509.0m / Total Assets 761.0m)
RoE = -63.01% (Net Income TTM -509.0m / Total Stockholder Equity 807.8m)
RoCE = -77.67% (EBIT -510.3m / Capital Employed (Total Assets 761.0m - Current Liab 104.0m))
RoIC = -61.39% (negative operating profit) (NOPAT -403.1m / Invested Capital 656.7m)
WACC = 8.42% (E(6.86b)/V(6.86b) * Re(8.42%) + D(72.0k)/V(6.86b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 8.42% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 96.69 | Cagr: 16.67%
[DCF] Fair Price = unknown (Cash Flow -395.0m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 2.64 | # QB: 1
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-12-31): EPS=-0.58 | Chg30d=+13.17% | Revisions=-25% | Analysts=3
EPS current Year (2027-03-31): EPS=-2.74 | Chg30d=+3.43% | Revisions=-50% | GrowthEPS=-11.2% | GrowthRev=+0.0%
EPS next Year (2028-03-31): EPS=-2.82 | Chg30d=-2.55% | Revisions=-50% | GrowthEPS=-2.8% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: -70% (up=0, down=7)